What is Collegium Pharmaceutical, Inc.'s belbuca — cost?

Collegium Pharmaceutical, Inc. (COLL) reported belbuca — cost of $360M in Q2 2026.

How has Collegium Pharmaceutical, Inc.'s belbuca — cost changed year-over-year?

Collegium Pharmaceutical, Inc.'s belbuca — cost decreased by 0.0% year-over-year, from $360M to $360M.

What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — cost?

Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — cost has grown at a -0.2% compound annual growth rate (CAGR), from $1.45B to $1.44B.

What does belbuca — cost mean?

Reflects the total direct costs associated with the production, distribution, and support of the Belbuca product line. Monitoring this helps evaluate the direct cost structure and gross margin efficiency of the specific product segment.

Collegium Pharmaceutical, Inc. (COLL) Belbuca — Cost

Screener

Other product segments

Azstarys

$635M—

Jornay PM

$635M0.0%

Symproic

$70M0.0%

Symproic and other

$70M0.0%

Similar metrics at other companies

SEICSEI Wealth Platform — Capitalized software development costs

$7.46M-15.8%

AMGNTAVNEOS — Finite-lived intangible assets, gross

$2.4B—

AMGNTAVNEOS, US Market — Finite-lived intangible assets, gross

$2.3B—

MNKDISPERSE License — Finite Lived Intangible Assets Gross

$4.3M—

MNKDOnbody Infusor — Finite Lived Intangible Assets Gross

$194M—

MNKDReady Flow Formulation — Finite Lived Intangible Assets Gross

$129.6M—

Other financials

Income statement

See full

Revenue$199.9M+6.3%

Gross profit$110.3M+1.8%

Operating income$3.7M-89.5%

Net income-$15.1M-226%

EPS (diluted)-$0.46-235%

Balance sheet

See full

Cash & equivalents$150.4M+8.8%

Total debt$5.0M-19.8%

Total equity$311.9M+34.3%

Total assets$2.1B+34.1%

Cash flow

See full

Operating cash flow$71.3M-1.5%

CapEx$496.0K+663%

Free cash flow$70.8M-2.1%

Valuation

See full

Market cap$955.82M-16.0%

Enterprise value$810.41M-19.5%

P/E20×-11.4×

P/S1.2×-0.4×

Profitability

See full

Gross margin60%+3.3pp

Operating margin19.5%+1.1pp

Net margin5.9%+0.8pp

FCF margin40.6%+10.8pp

Returns & leverage

See full

Return on equity17.6%+1.4pp

Debt / equity0×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 7:34 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-053851

Line item	June 30, 2026 / Cost	June 30, 2026 / Accumulated Amortization	June 30, 2026 / Carrying Amount	December 31, 2025 / Cost	December 31, 2025 / Accumulated Amortization	December 31, 2025 / Carrying Amount
Jornay PM	$635,000	$(152,986)	$482,014	$635,000	$(111,072)	$523,928
Azstarys	635,000	(7,480)	627,520	—	—	—
Belbuca	360,000	(322,305)	37,695	360,000	(284,607)	75,393
Nucynta Products	521,170	(521,170)	—	521,170	(493,478)	27,692
Symproic	70,000	(31,145)	38,855	70,000	(27,503)	42,497
Total intangible assets	$2,221,170	$(1,035,086)	$1,186,084	$1,586,170	$(916,660)	$669,510

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s belbuca — cost?: Collegium Pharmaceutical, Inc. (COLL) reported belbuca — cost of $360M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s belbuca — cost changed year-over-year?: Collegium Pharmaceutical, Inc.'s belbuca — cost decreased by 0.0% year-over-year, from $360M to $360M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — cost?: Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — cost has grown at a -0.2% compound annual growth rate (CAGR), from $1.45B to $1.44B.
What does belbuca — cost mean?: Reflects the total direct costs associated with the production, distribution, and support of the Belbuca product line. Monitoring this helps evaluate the direct cost structure and gross margin efficiency of the specific product segment.